Akcea Therapeutics, Inc. (NASDAQ:AKCA) headquartered in Boston, will host a conference call for the investment community to discuss the 2Q20 earnings result on 4th August 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.akceatx.com
Earnings Expectation
Akcea Therapeutics, Inc. is set to announce second quarter earning results on Tuesday 4th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, AKCA to report 2Q20 loss of $ 0.35 per share. For the full year, analysts anticipate top line of $ 112.53 million, while looking forward to loss of $ 1.63 per share bottom line.
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy.
